This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AstraZeneca's (AZN) Tagrisso sNDA Receives Priority Review
by Zacks Equity Research
AstraZeneca's (AZN) regulatory application for label expansion of Tagrisso to include adjuvant treatment of patients with early-stage EGFR-mutated lung cancer gets FDA's apriority review.
Biogen (BIIB) Q3 Earnings Top, Tecfidera Generics Hurt Sales
by Zacks Equity Research
Biogen (BIIB) beats third-quarter estimates for both earnings and sales. Tecfidera generics hurts sales, resulting in guidance cut.
Aptose (APTO) Initiates Phase I a/b Study in Leukemia Patients
by Zacks Equity Research
Aptose (APTO) doses first patient with acute myeloid leukemia in a phase I a/b study with CG-806, with a starting dose of 450 mg.
Bristol-Myers' (BMY) Opdivo Gets Positive CHMP View for ESCC
by Zacks Equity Research
The CHMP passes a favorable opinion for the approval of Bristol-Myers' (BMY) Opdivo to address advanced/ metastatic esophageal squamous cell carcinoma in the EU.
Roche (RHHBY), AbbVie's Leukemia Drug Venclexta Get Full FDA Nod
by Zacks Equity Research
Roche (RHHBY) and partner AbbVie obtain full FDA approval for leukemia drug, Venclexta, in combination with Vidaza or Dacogen or low-dose cytarabine (LDAC).
Biogen (BIIB) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on sales numbers of Tecfidera and Spinraza when Biogen (BIIB) reports third-quarter earnings.
Pharma Stock Roundup: J&J's Q3 Earnings, Pause on Coronavirus Studies & Other Updates
by Kinjel Shah
J&J (JNJ) beats Q3 estimates for earnings and sales. J&J and Lilly (LLY) pause studies on their coronavirus vaccine and antibody candidates, respectively.
Regeneron's (REGN) Inmazeb Ebola Treatment Gets FDA Approval
by Zacks Equity Research
Regeneron (REGN) gets FDA nod for its triple antibody cocktail for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients.
Bayer's Aliqopa Meets Primary Endpoint in Lymphoma Study
by Zacks Equity Research
Bayer's (BAYRY) Aliqopa combined with Rituxan met the primary endpoint of significantly prolonging PFS in a phase III study in patients with relapsed indolent non-Hodgkin's lymphoma.
Roche's (RHHBY) 9M20 Sales Affected by COVID-19 Outbreak
by Zacks Equity Research
Roche's (RHHBY) performance in the first nine months gets negatively impacted by coronavirus-related disruptions. Nevertheless, the diagnostics division maintains momentum.
Regeneron Gains on EUA Request for Coronavirus Treatment
by Zacks Equity Research
Regeneron's (REGN) stock up following the submission of a request to the FDA for granting an Emergency Use Authorization to its experimental COVID-19 treatment, REGN-COV2.
Bristol Myers (BMY) Gains on Positive Opdivo Data in NSCLC
by Zacks Equity Research
Bristol Myers' (BMY) shares gain as the phase III study evaluating Opdivo plus chemotherapy meets primary endpoint for the indication of NSCLC.
Top Stock Reports for Adobe, Costco & Union Pacific
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Adobe (ADBE), Costco Wholesale (COST) and Union Pacific (UNP).
Bristol Myers' Opdivo & Yervoy Win FDA Nod for Mesothelioma
by Zacks Equity Research
Bristol Myers' (BMY) Opdivo in combination with Yervoy gets an FDA approval for malignant pleural mesothelioma.
Regeneron, Gilead in Focus as Trump Tests COVID-19 Positive
by Zacks Equity Research
The biotech companies experimenting coronavirus treatments are in greater focus now as President Trump test COVID-19 positive.
Ionis' Alexander Disease Candidate Gets Orphan Drug Status
by Zacks Equity Research
The FDA assigns an orphan drug designation to Ionis' (IONS) pipeline candidate ION373 for treating patients with Alexander disease.
Pharma Stock Roundup: FDA Approves New Uses of PFE, JNJ & GSK's Drugs
by Kinjel Shah
New indications of Glaxo's (GSK) Nucala J&J's (JNJ) Simponi Aria and Pfizer's (PFE) Xeljanz get FDA's nod.
Regeneron Surges on Coronavirus Treatment Development Efforts
by Zacks Equity Research
Regeneron's (REGN) shares grow year to date owing to focus on developing a treatment for the novel coronavirus.
Regeneron's Coronavirus Antibody Cocktail Study Data Promising
by Zacks Equity Research
Regeneron (REGN) announces encouraging initial data from its seamless phase I/II/III study, evaluating antibody cocktail candidate, REGN-COV2, in non-hospitalized patients with COVID-19.
Infinity's Eganelisib Gets Fast Track Tag for Breast Cancer
by Zacks Equity Research
Infinity's (INFI) eganelisib, combined with a checkpoint inhibitor and chemotherapy, gets Fast Track designation by the FDA for the treatment of inoperable locally-advanced or metastatic TNBC in the first-line setting.
Blueprint Medicines Rises YTD on Robust Ayvakit Progress
by Zacks Equity Research
Blueprint Medicines' (BPMC) lead drug Ayvakyt/Ayvakit approved for PDGFRA Exon 18 mutant GIST is off to a solid start. The company's efforts to expand the drug's label are promising as well.
Ascendis Progresses With Hypoparathyroidism Drug TransCon PTH
by Zacks Equity Research
Ascendis Pharma (ASND) reports encouraging preliminary data on its hypoparathyroidism candidate, TransCon PTH. A late-stage study is anticipated to begin soon.
Bristol-Myers' Opdivo Meets Goals in Bladder Cancer Study
by Zacks Equity Research
Bristol-Myers' (BMY) Opdivo meets primary endpoint in a phase III study in patients with urothelial carcinoma.
AC Immune's Candidate Fails in Alzheimer's Disease Study
by Zacks Equity Research
The failure of AC Immune's (ACIU) study on Alzheimer's disease brings this challenging but promising space in focus.
AstraZeneca's Lynparza Gets CHMP Nod for Two New Indications
by Zacks Equity Research
AstraZeneca's (AZN) PARP inhibitor, Lynparza, nears approval as a treatment for prostate cancer, and first-line maintenance treatment for ovarian cancer in combination with Avastin in Europe.